Articles By Jack Cush, MD
RheumNow Podcast – Function Follows Form (10.2.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.
Read Article
Defining Difficult Rheumatoid Arthritis
‘Difficult-to-treat RA’ is an oft-used term that carries various clinical qualities and therapeutic disappointments. A EULAR Task Force was established to develop recommendations for the management of difficult-to-treat rheumatoid arthritis and as a first step, have put forth their definition of this rheumatoid arthritis (RA) subset.
Read Article
Low Risk of Latent TB with Secukinumab
TB reactivation and latent tuberculosis infection (LTBI) are warned against with biologic agents, especially TNF inhibitors; yet clinical trial data now shows that the risk of LTBI with IL-17 inhibition via secukinumab is uncommon.
Read Article
Hydroxychloroquine Fails as Pre-exposure Prophylaxis for COVID-19
Numerous previous studies have questioned the efficacy or protection afforded by hydroxychloroquine (HCQ) for COVID-19 and studies have show that HCQ has failed when given as post-exposure prophylaxis to health care workers (HCWs). A new randomized controlled trial has shown that HCQ failed when given as 8 weeks of pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19 patients.
Read Article
Filgotinib Approved by the EMA for Rheumatoid Arthritis
On Friday, Gilead and Galapagos announced that the European Commission (EC) has granted marketing authorization for filgotinib (trade name, Jyseleca) their oral, once-daily, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have resp
Read Article
Gabapentin Fails to Lessen Chronic Pelvic Pain
Lancet reports that in a randomized, blinded, controlled trial, gabapentin failed to significantly lower pain scores in women with chronic pelvic pain, and was associated with higher adverse event rates compared to placebo.
Read Article
RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.
Read Article
EULAR Updated 2019 Recommendations for Psoriatic Arthritis Management
In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.
Read Article
Romilkimab Effective in Early Diffuse Systemic Sclerosis
A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).
Read Article
Ustekinumab Early Risk for Cardiovascular Events
JAMA Dermatology reports a claims-based, case-time-controlled French study of 9290 psoriasis patients suggesting that ustekinumab initiation may be associated with an increased risk of acute coronary syndrome or stroke in high risk cardiovascular patients.
Read Article
